Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc Cabel

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Breast Cancer (Tokyo, Japan)|April 10, 2024
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastasesAlexandre De Moura, Delphine Loirat, Sarah Vaillant, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2023
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumabRomain-David Seban, Emilie Arnaud, Delphine Loirat, et al.
Fundamental & Clinical Pharmacology|October 22, 2017
Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French studyLuc Cabel, Benoit Blanchet, Audrey Thomas-Schoemann, et al.
Scientific Reports|November 7, 2025
Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie HospitalsAlexandre De Moura, Orane Gleizes, Luc Cabel, et al.
Cancers|March 24, 2019
Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer PatientsLuc Cabel, Charles Decraene, Ivan Bieche, et al.
JCO Precision Oncology|February 9, 2022
<i>ERBB3</i>-Activating Mutations in Small Bowel AdenocarcinomasLuc Cabel, Thomas Aparicio, Ivan Bieche, et al.
Oncogene|February 27, 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysisAntoine Vasseur, Luc Cabel, Caroline Hego, et al.
Breast Cancer Research : BCR|March 7, 2021
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patientsLauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, et al.
Breast Cancer Research : BCR|May 29, 2020
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris areaPerrine Vuagnat, Maxime Frelaut, Toulsie Ramtohul, et al.
Oncogene|February 12, 2020
A single droplet digital PCR for ESR1 activating mutations detection in plasmaEmmanuelle Jeannot, Lauren Darrigues, Marc Michel, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Breast Cancer (Tokyo, Japan)|April 10, 2024
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastasesAlexandre De Moura, Delphine Loirat, Sarah Vaillant, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2023
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumabRomain-David Seban, Emilie Arnaud, Delphine Loirat, et al.
Fundamental & Clinical Pharmacology|October 22, 2017
Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French studyLuc Cabel, Benoit Blanchet, Audrey Thomas-Schoemann, et al.
Scientific Reports|November 7, 2025
Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie HospitalsAlexandre De Moura, Orane Gleizes, Luc Cabel, et al.
Cancers|March 24, 2019
Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer PatientsLuc Cabel, Charles Decraene, Ivan Bieche, et al.
JCO Precision Oncology|February 9, 2022
<i>ERBB3</i>-Activating Mutations in Small Bowel AdenocarcinomasLuc Cabel, Thomas Aparicio, Ivan Bieche, et al.
Oncogene|February 27, 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysisAntoine Vasseur, Luc Cabel, Caroline Hego, et al.
Breast Cancer Research : BCR|March 7, 2021
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patientsLauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, et al.
Breast Cancer Research : BCR|May 29, 2020
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris areaPerrine Vuagnat, Maxime Frelaut, Toulsie Ramtohul, et al.
Oncogene|February 12, 2020
A single droplet digital PCR for ESR1 activating mutations detection in plasmaEmmanuelle Jeannot, Lauren Darrigues, Marc Michel, et al.
Pageof 8